POLQ identifies a better response subset to immunotherapy in muscle‐invasive bladder cancer with high PD‐L1

POLQ identifies a better response subset to immunotherapy in muscle‐invasive bladder cancer with high PD‐L1

Abstract Background Though programmed cell death‐ligand 1 (PD‐L1) has been used in predicting the efficacy of immune checkpoint blockade (ICB), it is insufficient as a single biomarker. As a key effector of an intrinsically mutagenic microhomology‐mediated end joining (MMEJ) pathway, DNA polymerase...

Description complète

Détails bibliographiques
Auteurs principaux: Ge Liu, Kaifeng Jin, Zhaopei Liu, Xiaohe Su, Ziyue Xu, Bingyu Li, Jingtong Xu, Yuan Chang, Yiwei Wang, Yu Zhu, Le Xu, Jiejie Xu, Zewei Wang, Hailong Liu, Weijuan Zhang
Format: Article
Langue:English
Publié: Wiley 2024-02-01
Collection:Cancer Medicine
Sujets:
immunotherapy
muscle‐invasive bladder cancer
PD‐L1
platinum‐based chemotherapy
POLQ
Accès en ligne:https://doi.org/10.1002/cam4.6962

Internet

https://doi.org/10.1002/cam4.6962

Documents similaires